Highly selective sigma receptor ligands and radioligands as probes in nociceptive processing and the pathphysiological study of memory deficits and cognitive disorders

Patent metadata

Field	Value
Publication number	US-9724435-B2
Application number	US-201414196483-A
Country	US
Kind code	B2
Filing date	Mar 4, 2014
Priority date	Aug 16, 2007
Publication date	Aug 8, 2017
Grant date	Aug 8, 2017

Abstract

A method for localizing and quantifying S1R role in nociceptive processing; for providing a guide to providing an analgesic therapy; of using an S1R selective ligand as a biomarker for pathphysiological study of memory deficits and cognitive disorders; or of detecting increased S1R density at the site of nerve injury arising from neuropathic pain comprising using as a probe at least one SR1 selective compound or radioligand of the general formula III′, or IV′:

First claim

We claim:

1. A method of detecting increased S1R density at the site of nerve injury arising from neuropathic pain comprising S1R-PET imaging a tissue with an imaging agent to determine a non-invasive biomarker of nerve injury and inflammation wherein the imaging agent comprises at least one SR1 selective compound or radioligand selected from the general formula III′, or IV′

wherein R 1 is a radical of an optionally substituted piperazine, an optionally substituted tetrahydropyridine, an optionally substituted azepane or an optionally substituted tetrahydroisoquinoline in which the optional substituents are on the aromatic moiety or isoindoline-1,3-dione; R 2,4,5 are each independently any one or combinations of the following moieties, hydrogen, cyano, nitro, acyl, alkyl, amido, azido, isothiocyanate, isocyanate, optionally substituted anilino, halogens, ethers, sulfonamides, thioacyl, nitro, aromatic, heterocyclic, olefinic, acetylene, deuterium, or tritium; Z is O, “n” is 1 to 5 carbons in length; wherein the moiety bridging R 1 and N is a substituted alkylene; and wherein X is or C 1 -C 4 radiohaloalkyl; and stereoisomers, or pharmaceutically acceptable salts thereof.

2. The method of claim 1 , wherein the optionally substituted N-containing heterocyclic radical is an optionally substituted azepane.

3. The method of claim 1 , having the formula XII′

4. The method of claim 1 , where R1 is optionally substituted

5. The method of claim 1 , wherein X is F 18 C 1 -C 4 alkyl.

Assignees

• The Univ Of Mississippi
• Univ Leland Stanford Junior

Inventors

• Mccurdy Christopher R
• Mesangeau Christophe
• Chin Frederick T
• James Michelle L
• Shen Bin
• Gambhir Sanjiv
• Biswal Sandip
• Behera Deepak

Classifications

• C07D279/16

  condensed with one six-membered ring · CPC title

• C07D209/08

  with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring · CPC title

• C07D417/06

  linked by a carbon chain containing only aliphatic carbon atoms · CPC title

• A61K31/428

  condensed with carbocyclic rings · CPC title

• A61K51/0459

  having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine · CPC title